Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.
In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.
The combination therapy of cilofexor (CILO) and firsocostat (FIR) missed the primary endpoint but achieved improvements in other secondary parameters including fibrosis markers, disease activity, and liver function in patients with fibrosis due to NASH*, according to the ATLAS trial presented at digital ILC 2020.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
A trivalent vaccine against hepatitis (Hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver-related deaths and is associated with a variety of malignancies, according to a new study presented at the Digital International Liver Congress (ILC) 2020.
Faecal microbiota transplantation (FMT) may be a viable treatment option for patients with severe alcoholic hepatitis (SAH), reports a study presented at the Digital International Liver Congress (ILC) 2020.
In the treatment of patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), the first-in-class GLP-1/glucagon dual-receptor agonist cotadutide confers positive effects on body weight, alanine aminotransferase levels, and markers of liver fat and fibrosis, although these benefits appear to come with adverse gastrointestinal events, as shown in a phase IIb study.
Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.